To support future clinical studies, in vitro susceptibility tests were examined to determine whether Neisseria gonorrhoeae could be tested reliably against two 1-lactam-clavulanate combinations. All isolates that were tested appeared to be susceptible to amoxicillin and ticarcillin in combination with clavulanic acid. In the absence of resistant isolates, only a breakpoint for a susceptible category could be defined for agar dilution tests with amoxicillin-clavulanic acid (MIC of s 2.0/1.0 ,ug/ml is tentatively proposed). For disk diffusion tests, a corresponding breakpoint zone diameter of 228 mm is suggested. The validity of the breakpoints for penicillinase-negative penicillin-resistant strains awaits clinical data. Proposed quality control limits for testing amoxicillin-clavulanic acid by agar dilution and disk diffusion methods are a MIC of 0.25/0.125 to 1.0/0.5 ,ug/ml and zones of 30 to 40 mm in diameter for N. gonorrhoeae ATCC 49226, a MIC of 0.125/0.06 to 0.5/0.25 jg/ml for Staphylococcus aureus ATCC 29213, and zones of 30 to 38 mm for S. aureus ATCC 25923. Ticarcillinclavulanate is currently tested against other species by preparing doubling dilutions of ticarcillin with a constant 2 ,ug of clavulanate per ml. By that method, all gonococci were susceptible to low concentrations. However, the amount of clavulanic acid that is included (2 jug/ml) will, by itself, inhibit many strains of N. gonorrhoeae.
Penicillinase-producing Neisseria gonorrhoeae (PPNG) was first recognized and reported in the mid-1970s (1, 2, 20) . Since then, the prevalence of PPNG has increased to the point that 3-lactams such as penicillin and ampicillin are unreliable and no longer the drugs of choice in the empirical therapy of gonorrhea (3) . The 1-lactamases of PPNG are readily inhibited by sodium clavulanate (12) . The natural extension of this was the treatment of gonorrhea with ,-lactam-clavulanate combinations. However, most of the reported studies used amoxicillin (3 g) with either 125 or 250 mg of clavulanate, which is substantially less clavulanate than that used in the current American formulations of this combination. In earlier studies, the cure rate for uncomplicated PPNG infections ranged from 63 to 96% (5-9, 13, 17) . In one study involving anogenital and rectal gonorrhea, the cure-rate was 36% (21) . In the only report we found in which PPNG infections were treated with a 2:1 formulation of amoxicillin-clavulanate, the cure rate for 134 patients was 100% (18) . Thus, it appears that amoxicillin-clavulanate as currently formulated may be an effective drug for the treatment of uncomplicated gonorrhea, including cases caused by PPNG.
The other P-lactam currently available in combination with clavulanate is ticarcillin. Although this combination would not normally be considered in the treatment of uncomplicated gonorrhea, it has been reported to be efficacious in the treatment of various deep pelvic infections, including pelvic inflammatory disease (10, 11, 19) . Since pelvic inflam-* Corresponding author. matory disease is often initiated by N. gonorrhoeae, the continued efficacy of ticarcillin-clavulanate against this agent should be monitored periodically. The reliability of in vitro tests that measure susceptibility to that combination needs to be documented.
Although neither of these combination drugs is currently among those recommended for the treatment of gonorrhea, clinical studies evaluating amoxicillin-clavulanate for that purpose are extant. We undertook in vitro studies to determine whether the resistance or susceptibility of gonococci could be measured reliably. The present study describes interpretive criteria and quality control parameters for use in clinical studies when such combination drugs are tested against N. gonorrhoeae.
To determine interpretive criteria for amoxicillin-clavulanic acid, 102 N. gonorrhoeae isolates were tested. These included 21 PPNGs (penicillin MICs: 2.0 to >32 jug/ml) and 81 penicillinase-negative N. gonorrhoeae (PNNG) isolates, which included 20 penicillin-resistant (penicillin MICs: 1.0 to 8.0 ,ug/ml) and 61 penicillin-susceptible or moderately susceptible strains (penicillin MICs: c0.03 to 0.5 jug/ml). Each isolate was tested in triplicate by both agar dilution and disk diffusion methods, following the procedures recommended by the National Committee for Clinical Laboratory Standards (14) (15) (16) . Disks contained 20/10 ,ug of amoxicillinclavulanate, and for agar dilution tests, the drugs were combined in 2:1 ratios with twofold dilution concentrations ranging from 4/2 to 0.004/0.002 ,ug/ml. Ticarcillin-clavulanate was tested by using disks containing 75 jug of ticarcillin and 10 jug of clavulanate and agar dilution concentrations of ticarcillin ranging from 4.0 to 0.003 ,ug/ml with a constant 2.0 
